238 related articles for article (PubMed ID: 17695482)
1. Efficacy of IL-2 immunotherapy in metastatic renal cell carcinoma in relation to the psychic profile as evaluated using the Rorschach test.
Messina G; Lissoni P; Bartolacelli E; Fumagalli L; Brivio F; Colombo E; Gardani GS
Anticancer Res; 2007; 27(4C):2985-8. PubMed ID: 17695482
[TBL] [Abstract][Full Text] [Related]
2. Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2.
Lissoni P; Bordin V; Vaghi M; Fumagalli L; Bordoni A; Mengo S; Bucovec R; Fumagalli E; Malugani F; Ardizzoia A; Giani L; Gardani GS; Tancini G
Anticancer Res; 2002; 22(2B):1061-4. PubMed ID: 12168901
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
4. A psychoncological study of lymphocyte subpopulations in relation to pleasure-related neurobiochemistry and sexual and spiritual profile to Rorschach's test in early or advanced cancer patients.
Messina G; Lissoni P; Bartolacelli E; Tancini G; Villa S; Gardani GS; Brivio F
J Biol Regul Homeost Agents; 2003; 17(4):322-6. PubMed ID: 15065761
[TBL] [Abstract][Full Text] [Related]
5. Standard interleukin-2 (IL-2) and interferon-alpha immunotherapy versus an IL-2 and 4-epirubicin immuno-chemotherapeutic association in metastatic renal cell carcinoma.
Naglieri E; Gebbia V; Durini E; Lelli G; Abbate I; Selvaggi FP; Di Tonno P; Colucci G
Anticancer Res; 1998; 18(3B):2021-6. PubMed ID: 9677460
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone.
Lissoni P; Rovelli F; Baiocco N; Tangini G; Fumagalli L
Anticancer Res; 2001; 21(1B):777-9. PubMed ID: 11299843
[TBL] [Abstract][Full Text] [Related]
7. Physiopathology of IL-12 in human solid neoplasms: blood levels of IL-12 in early or advanced cancer patients, and their variations with surgery and immunotherapy.
Lissoni P; Mengo S; Mandalà M; Mauri E; Brivio F; Rovelli F; Confalonieri G; Longarini R; Bonfante A; Folli D; Meregalli S; Barni S; Tancini G; Giani L
J Biol Regul Homeost Agents; 1998; 12(1-2):38-41. PubMed ID: 9677534
[TBL] [Abstract][Full Text] [Related]
8. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
[TBL] [Abstract][Full Text] [Related]
9. Reactivation of a normal endogenous secretion of interleukin-2 in metastatic cancer patients by a chronic subcutaneous injection of interleukin-2.
Di Felice G; Fumagalli L; Majorca F; Barni S; Ardizzoia A; Tancini G; Lissoni P
J Biol Regul Homeost Agents; 1996; 10(4):98-9. PubMed ID: 9604779
[TBL] [Abstract][Full Text] [Related]
10. Fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: no in vivo effect of Fas ligand tumor counterattack.
Donskov F; von der Maase H; Marcussen N; Hamilton-Dutoit S; Madsen HH; Jensen JJ; Hokland M
Clin Cancer Res; 2004 Dec; 10(23):7911-6. PubMed ID: 15585624
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral administration of a 1,2-dimyristyloxypropyl-3- dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma.
Galanis E; Burch PA; Richardson RL; Lewis B; Pitot HC; Frytak S; Spier C; Akporiaye ET; Peethambaram PP; Kaur JS; Okuno SH; Unni KK; Rubin J
Cancer; 2004 Dec; 101(11):2557-66. PubMed ID: 15517589
[TBL] [Abstract][Full Text] [Related]
12. Clinical and biological effects of interleukin-2 with or without a concomitant administration of granulocyte-macrophage colony-stimulating factor in metastatic cancer patients.
Lissoni P; Mengo S; Bucovec R; Brivio F; Fumagalli L; Tancini G; Gardani GS
In Vivo; 2003; 17(1):73-5. PubMed ID: 12655794
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place.
Wagner JR; Walther MM; Linehan WM; White DE; Rosenberg SA; Yang JC
J Urol; 1999 Jul; 162(1):43-5. PubMed ID: 10379736
[TBL] [Abstract][Full Text] [Related]
14. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival.
Walther MM; Johnson B; Culley D; Shah R; Weber J; Venzon D; Yang JC; Linehan WM; Rosenberg SA
J Urol; 1998 Mar; 159(3):718-22. PubMed ID: 9474133
[TBL] [Abstract][Full Text] [Related]
15. The longitudinal relationship between the systemic inflammatory response, circulating T-lymphocytes, interleukin-6 and -10 in patients undergoing immunotherapy for metastatic renal cancer.
Ramsey S; Aitchison M; Graham J; McMillan DC
BJU Int; 2008 Jul; 102(1):125-9. PubMed ID: 18336617
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma.
Thompson JA; Figlin RA; Sifri-Steele C; Berenson RJ; Frohlich MW
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3562-70. PubMed ID: 14506142
[TBL] [Abstract][Full Text] [Related]
17. Chronically administered immunotherapy with low-dose IL-2 and IFN-alpha in metastatic renal cell carcinoma: a feasible option for patients with a good prognostic profile.
Vaglio A; Alberici F; Maggiore U; Buti S; Potenzoni D; Passalacqua R; Buzio C
Oncology; 2009; 76(1):69-76. PubMed ID: 19047813
[TBL] [Abstract][Full Text] [Related]
18. Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system.
Lissoni P; Malugani F; Malysheva O; Kozlov V; Laudon M; Conti A; Maestroni G
Neuro Endocrinol Lett; 2002 Aug; 23(4):341-4. PubMed ID: 12195238
[TBL] [Abstract][Full Text] [Related]
19. Correlation between pretreatment serum levels of neopterin and response to interleukin-2 immunotherapy in cancer patients.
Lissoni P; Barni S; Ardizzoia A; Scardino E; Tancini G; Viganò MG
J Biol Regul Homeost Agents; 1995; 9(1):21-3. PubMed ID: 8553904
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of large doses of IL-2-activated human leukocyte antigen haploidentical peripheral blood stem cells on refractory metastatic renal cell carcinoma.
Cao S; Wang YL; Ren XB; Yu JP; Ren BZ; Zhang XW; Zhang WH; Han Y
Cancer Biother Radiopharm; 2011 Aug; 26(4):503-10. PubMed ID: 21812652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
